Validation of a flow cytometric acridine orange micronuclei methodology in rats

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 528, Issue 1-2, 2003, Pages 1-18

  Criswell, K A ^a   Krishna, G ^a   Zielinski, D ^a   Urda, G A ^a   Juneau, P ^a   Bulera, S ^a   Bleavins, M R ^a  

^a PFIZER INC   (United States)

Author keywords

1,2 Dimethylhydrazine; Acridine orange; Bone marrow toxicity; Chlorambucil; Doxorubicin; Methotrexate; Micronucleus; Rat; Vincristine

Indexed keywords

1,2 DIMETHYLHYDRAZINE; ACRIDINE ORANGE; CHLORAMBUCIL; DOXORUBICIN; METHOTREXATE; VINCRISTINE;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL COUNT; CYTOTOXICITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; FLOW CYTOMETRY; LABORATORY TEST; MALE; METHODOLOGY; MICRONUCLEUS; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; RAT; VALIDATION PROCESS;

EID: 0038107794     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(03)00077-0     Document Type: Article

References (26)

1. International Conference on Harmonization Guidelines, Genotoxicity: A Standard Battery for Genotoxicity Testing of Pharmaceuticals, Step 4, 1999 (Document).
2. MacGregor J.T., Casciano D., Muller L. Strategies and testing methods for identifying mutagenic risks. Mutat. Res. 455:2000;3-20.
3. Gollapudi B., Krishna G. Practical aspects of mutagenicity testing strategy: an industrial perspective. Mutat. Res. 455:2000;21-28.
4. Krishna G., Hayashi M. In vivo rodent micronucleus assay: protocol. Mutat. Res. 455:2000;155-166.
5. Mavournin K.H., Blakey D.H., Cimino M.C., Salamone M.F., Heddle J.A. The in vivo micronucleus assay in mammalian bone marrow and peripheral blood: a report of the US Environmental Protection Agency Gene-Tox Program. Mutat. Res. 239:1990;29-80.
6. Schmid W. The micronucleus test. Mutat. Res. 31:1975;9-15.
7. MacGregor J.T., Heddle J.A., Hite M., Margolin B.H., Ramel C., Salamone M.F., Tice R.R., Wild D. Guidelines for the conduct of micronucleus assays in mammalian bone marrow erythrocytes. Mutat. Res. 189:1987;103-112.
8. Hayashi M., Tice R.R., MacGregor J.T., Anderson D., Blakely D.H., Kirsh-Volders M., Oleson F.B. Jr., Pacchierotti F., Romagna F., Shimada H. In vivo rodent erythrocyte micronucleus assay. Mutat. Res. 312:1994;293-304.
9. Heddle J.A., Hite M., Kirkhart B., Mavournin K., MacGregor J.T., Newell G.W., Salamone M.F. The induction of micronuclei as a measure of genotoxicity: a report of the US Environmental Protection Agency Gene-Tox Program. Mutat. Res. 123:1983;61-118.
10. Krishna G., Urda G., Theiss J. Principles and practices of integrating genotoxicity evaluation into routine toxicology studies: a pharmaceutical industry perspective. Environ. Mol. Mutagen. 32:1998;115-120.
11. Hayashi M., MacGregor J.T., Gatehouse D.G., Adler I., Blakey D.H., Dertinger S.D., Krishna G., Morita T., Russo A., Sutou S. In vivo rodent erythrocyte micronucleus assay. Part II. Some aspects of protocol design including repeated treatments, integration with toxicity testing, and automated scoring. Environ. Mol. Mutagen. 35:2000;234-252.
12. Criswell K.A., Krishna G., Zielinski D., Urda G., Theiss J., Juneau P., Bleavins M.R. Use of acridine orange in: flow cytometric evaluation of erythropoietic cytotoxicity. Mutat. Res. 414:1998;49-61.
13. Criswell K.A., Krishna G., Zielinski D., Urda G., Theiss J., Juneau P., Bleavins M.R. Use of acridine orange in: flow cytometric evaluation of micronuclei induction. Mutat. Res. 414:1998;63-75.
14. Lesesve J.F., Lacombe F., Marit G., Bernard P., Belloc F., Reiffers J. High fluorescence reticulocytes are an indicator of bone marrow recovery after chemotherapy. Eur. J. Haematol. 54:1995;61-63.
15. Watanabe K., Kawai Y., Takeuchi K., Shimizu N., Iri H., Ideda Y., Houwen B. Reticulocyte maturity as an indicator for estimating qualitative abnormality of erythropoiesis. J. Clin. Pathol. 47:1994;736-739.
16. Jordan A., Hadfield J.A., Lawrence N.J., McGowan A.T. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med. Res. Rev. 18:1998;259-296.
17. Huitema A.D., Smits K.D., Mathot R.A., Schellens J.H., Rodenhuis S., Beijnen J.H. The clinical pharmacology of alkylating agents in high-dose chemotherapy. Anticancer Drugs. 11:2000;515-533.
18. Grosflam J., Weinblatt M.E. Methotrexate mechanism of action, pharmacokinetics, clinical indications, and toxicity. Curr. Opin. Rheumatol. 3:1991;363-368.
19. Aubel-Sadron G., Londos-Gagliardi D. Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review. Biochimie. 66:1984;333-352.
20. Muller I., Niethammer D., Bruchelt G. Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity. Int. J. Mol. Med. 1:1998;491-494.
21. Choudhary G., Hansen H. Human health perspective on environmental exposure to hydrazines: a review. Chemosphere. 37:1998;801-843.
22. Albanese R., Mirkova E., Gatehouse D., Ashby J. Species-specific response to the rodent carcinogens 1,2-dimethylhydrazine and 1,2-dibromo-3-chloropropane in rodent bone marrow micronucleus assays. Mutagenesis. 3:1988;35-38.
23. Cliet I., Melcion C., Cordier A. Lack of predictivity of bone marrow micronucleus test versus testis micronucleus test: comparison of four carcinogens. Mutat. Res. 292:1993;105-111.
24. Goldberg M.T., Blakey D.H., Bruce W.R. Comparison of the effects of 1,2-dimethylhydrazine and cyclophosphamide on micronucleus incidence in bone marrow and colon. Mutat. Res. 109:1983;91-98.
25. Abramsson-Zetterberg L., Grawe J., Zetterberg G. The micronucleus test in rat erythrocytes from bone marrow, spleen and peripheral blood: the response to low doses of ionizing radiation, cyclophosphamide and vincristine determined by flow cytometry. Mutat. Res. 423:1999;113-124.
26. Dertinger S., Torous D., Hall N., Tometsko C., Gasiewicz T. Malaria-infected erythrocytes serve as biological standards to ensure reliable and consistent scoring of micronucleated erythrocytes by flow cytometry. Mutat. Res. 464:2000;195-200.